Combined inhibition of MCL1 and BCL-2 with AMG 176 and venetoclax induces anti-tumor effects in primary patient samples and models of acute myeloid leukemia

被引：0
|
作者：
Caenepeel, Sean R. [1 ]
Osgood, Tao [1 ]
Belmontes, Brian [1 ]
Sun, Jan [1 ]
Cajulis, Elaina [1 ]
Wei, Andrew [2 ]
Coxon, Angela [1 ,3 ]
Canon, Jude [1 ]
Hughes, Paul [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Alfred Hosp, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3972
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3972
引用
收藏
页数：2
相关论文
共 40 条
  • [21] The MDM2 inhibitor AMG 232 causes tumor regression and potentiates the anti-tumor activity of MEK inhibition and DNA-damaging cytotoxic agents in preclinical models of acute myeloid leukemia
    Canon, Jude R.
    Osgood, Tao
    Saiki, Anne Y.
    Oliner, Jonathan D.
    CANCER RESEARCH, 2016, 76
  • [22] Co-Targeting BCL-2 and MCL1 (via CDK9) in Pre-Clinical Models of High-Risk Acute Lymphoblastic Leukemia
    Moujalled, Donia M.
    Khaw, Seong Lin
    Sadras, Teresa
    Pomilio, Giovanna
    Morley, Thomas
    Litalien, Veronique
    Ludlow, Louise
    Ekert, Paul G.
    Hanna, Diane
    BLOOD, 2024, 144 : 1419 - 1420
  • [23] Inhibition of the JAK/STAT and Bcl-2 Pathways Enhances Anti-Tumor Effects in an in Vitro model of T-Cell Acute Lymphoblastic Leukemia (T-ALL)
    Gavcovich, Tara Bree
    Walker, Kirsti Lorraine
    Bouchlaka, Myriam N.
    Capitini, Christian M.
    BLOOD, 2015, 126 (23)
  • [24] Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models
    Cai, Tianyu
    Kuruvilla, Vinitha Mary
    Lin, Xiaoyu
    Uziel, Tamar
    Lu, Xin
    Zhang, Lu
    Huang, Xiaoli
    Zhang, Qi
    Cavazos, Antonio
    Han, Lina
    Shen, Yu
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [25] Selective targeting BET family BDII bromodomain with ABBV-744 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
    Cai, Tianyu
    Kuruvilla, Vinitha
    Lin, Xiaoyu
    Uziel, Tamar
    Lu, Xin
    Zhang, Lu
    Zhang, Qi
    Han, Lina
    Cavazos, Antonio
    Shen, Yu
    Konopleva, Marina
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia
    Luedtke, Daniel A.
    Su, Yongwei
    Edwards, Holly
    Lin, Hai
    Taub, Jeffrey W.
    Ge, Yubin
    BLOOD, 2017, 130
  • [27] Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
    Bing Z. Carter
    Po Yee Mak
    Wenjing Tao
    Edward Ayoub
    Lauren B. Ostermann
    Xuelin Huang
    Sanam Loghavi
    Steffen Boettcher
    Yuki Nishida
    Vivian Ruvolo
    Paul E. Hughes
    Phuong K. Morrow
    Torsten Haferlach
    Steven Kornblau
    Muharrem Muftuoglu
    Michael Andreeff
    Blood Cancer Journal, 13
  • [28] Induction of apoptosis and anti-tumor effects of a novel pan inhibitor of Bcl-2 and Mcl-1 apogossypolone (ApoG2) in multiple myeloma cells.
    Lin, Jie
    Wu, Yongji
    Wang, Shujie
    Yang, Dajun
    Zhao, Yongqiang
    BLOOD, 2006, 108 (11) : 735A - 735A
  • [29] Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models
    Izadi, Hooman
    Hoang, Tiffany
    Ibrahim, Noah
    Pinchman, Joseph
    Boren, Brant C.
    Ma, Jianhui
    de Jong, Petrus R.
    Li, Jiali
    Bunker, Kevin D.
    Samatar, Ahmed A.
    Donate, Fernando
    CANCER RESEARCH, 2022, 82 (12)
  • [30] 225Ac-CD33 Radioimmunotherapy potently increases the sensitivity of resistant acute myeloid leukemia lines to the Bcl-2 inhibitor venetoclax by mediating a reduction in cellular Mcl-1 levels
    Garg, Ravendra
    Geoghegan, Eileen
    Allen, Kevin J.
    Dawicki, Wojciech
    Dadachova, Ekaterina
    Ludwig, Dale L.
    CANCER RESEARCH, 2019, 79 (13)
1234